There are currently 25 vaccines to fight COVID-19 in clinical evaluation, another 139 vaccines in a pre-clinical stage, and many more being researched.
But many of those vaccines, if they are at all successful, might not produce an immune response in portions of the population. That’s because some people’s bodies will react differently to the materials in the vaccine that are supposed to stimulate virus-fighting T cells.
And so just figuring out how much coverage a vaccine has, meaning, how many people it will stimulate to mount an immune response, is a big part of the vaccine puzzle.
With that challenge in mind, scientists at Massachusetts Institute of Technology on Monday unveiled a machine learning approach that can predict the probability that a particular vaccine design will reach a certain proportion of the population. That doesn’t mean they can guarantee its effectiveness, but the scientists’ work can aid in knowing up-front whether a given vaccine will have large gaps in who it can help.
The good news is, the MIT scholars have used their approach to design a novel COVID-19 vaccine on the computer that has far better coverage than many of the designs that have been published in the literature this year. They’re now testing the design in animals.
The bad news is, there could very well be large gaps in coverage of some of the existing vaccines already being explored by companies and labs, according to one of the authors of the report, David K. Gifford, who is with MIT’s Computer Science and Artificial Intelligence Laboratory.
“While they may protect more than 50% of the population, certain individuals and older individuals may not be protected,” Gifford told ZDNet in an email, when asked about vaccines currently under trial and in development.
The long path to a vaccine
Vaccines in development were not the direct subject of the work. Most of those vaccines are closed designs; no one knows exactly how they are composed. Instead, Gifford and colleagues designed vaccines from scratch, and then analyzed how effective they are, and extrapolated the findings to a group of vaccines whose composition is known.
Based on that, one can infer there might be problems with vaccines whose exact composition is not known.
It must be borne in mind that any in silico vaccine design such as the kind discussed here is only the beginning of a process that can take years to go through in vivo testing, in animals and then in humans, to establish both safety (non-toxicity), and efficacy, meaning that it actually confers a significant immune response.
But the work shows the ability of large computer models to dramatically speed up the initial work of searching through many, many possible combinations within a universe of possible ingredients, a search that can itself take years at the front end of a drug development pipeline.
This is the latest in large-scale, in-silico efforts against pathogens seen this year from MIT. Back in March, ZDNet reported on how MIT scientists used large-scale machine learning to search many combinations of compounds to come up with a novel antibiotic for a germ nothing else could kill.
Image Credit: Amanda Scott/Envato
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases for the last three decades and an expert on pandemics for the last four decades, has been optimistic on a vaccine arriving [...]
he United States has recorded 5 million confirmed coronavirus cases, while almost 20 million people are infected worldwide, according to Johns Hopkins University. Outside of the US, Brazil recorded more than 3 million cases, [...]
According to the first phase results, 90 per cent of the patients'lungs are still in a damaged state, which means their lungs ventilation and gas exchange functions have not recovered 90% of an example [...]
There are currently 25 vaccines to fight COVID-19 in clinical evaluation, another 139 vaccines in a pre-clinical stage, and many more being researched. But many of those vaccines, if they are at all successful, might [...]
A new class of nanosensor developed in Brazil could more accurately identify dengue and Zika infections, a task that is complicated by their genetic similarities and which can result in misdiagnosis. The technique uses [...]
Scientists investigating the evolution of the virus that causes Covid19 say that its mutation seems to be directed by human proteins that degrade it, but natural selection of the virus enables it to bounce [...]
Biomedical engineers at the Tufts University School of Engineering have developed tiny lipid-based nanoparticles that incorporate neurotranmitters to help carry drugs, large molecules, and even gene editing proteins across the blood-brain barrier and into [...]
UC San Diego recently announced that its health radiologists and other physicians are now leveraging artificial intelligence (AI) to augment lung-imaging analysis in a clinical research study aimed at COVID-19 lung imaging analysis. The cause of [...]
The hubbub around mutations in the virus that causes COVID-19—and how they might make it more infectious—has been around since the early phase of the pandemic. A preprint study about a particular mutation involving [...]
Human trials of a potential coronavirus vaccine being developed by scientists in Oxford are reported to have shown promising results. The researchers believe they have made a breakthrough after discovering the jab could provide “double protection” [...]
Researchers at MIT and Brigham and Women’s Hospital have designed a new face mask that they believe could stop viral particles as effectively as N95 masks. Unlike N95 masks, the new masks were designed [...]
Doctors may be missing signs of serious and potentially fatal brain disorders triggered by coronavirus, as they emerge in mildly affected or recovering patients, scientists have warned. Neurologists are on Wednesday publishing details of [...]
University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna [...]
Despite its advantages over other vaccine technologies for Covid-19, adenovirus vector vaccines are likely to be tripped up by pre-existing antibodies to the vectors used and the need for a second injection to boost [...]
When the first coronavirus cases in Chicago appeared in January, they bore the same genetic signatures as a germ that emerged in China weeks before. But as Egon Ozer, an infectious-disease specialist at the Northwestern University [...]
Park Systems presents “NanoScientific Symposium on Nano Applications for a Changing World” sponsored by Physics World and Nanotechnology World Association. Park Systems launched this online event for researchers and scientists in nanoscience and nanotechnology [...]